Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1979 1
1982 1
1984 1
1985 1
1986 1
1987 2
1988 2
1989 3
1990 3
1991 3
1992 4
1993 1
1994 2
1995 5
1996 2
1997 4
1998 6
1999 6
2000 2
2001 1
2002 4
2003 6
2004 4
2005 8
2006 7
2007 7
2008 11
2009 10
2010 17
2011 18
2012 22
2013 27
2014 19
2015 23
2016 25
2017 21
2018 7
2019 10
2020 5
2021 5
2022 4
2023 1
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
A randomized control trial of high-dose micronutrient-antioxidant supplementation in healthy persons with untreated HIV infection.
Wobeser WL, McBane JE, Balfour L, Conway B, Gill MJ, Huff H, Kilby DLP, Fergusson DA, Mallick R, Mills EJ, Muldoon KA, Rachlis A, Ralph ED, Rosenes R, Singer J, Singhal N, Tan D, Tremblay N, Vo D, Walmsley SL, Cameron DW; MAINTAIN Study Group. Wobeser WL, et al. Among authors: rachlis a. PLoS One. 2022 Jul 14;17(7):e0270590. doi: 10.1371/journal.pone.0270590. eCollection 2022. PLoS One. 2022. PMID: 35834528 Free PMC article. Clinical Trial.
Zidovudine (Retrovir) update.
Rachlis AR. Rachlis AR. CMAJ. 1990 Dec 1;143(11):1177-85. CMAJ. 1990. PMID: 2224694 Free PMC article. Review.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, Rauch A, Mugglin C, Klein M, van der Valk M, Smit C, Jarrin I, Berenguer J, Lacombe K, Requena MB, Wittkop L, Leleux O, Bonnet F, Salmon D, Matthews GV, Guy R, Martin NK, Spelman T, Prins M, Stoove M, Hellard M; InCHEHC Collaboration. Sacks-Davis R, et al. Lancet HIV. 2024 Feb;11(2):e106-e116. doi: 10.1016/S2352-3018(23)00267-9. Epub 2024 Jan 12. Lancet HIV. 2024. PMID: 38224708
Routinized Syphilis Screening Among Men Living With Human Immunodeficiency Virus: A Stepped Wedge Cluster Randomized Controlled Trial.
Burchell AN, Tan DHS, Grewal R, MacPherson PA, Walmsley S, Rachlis A, Andany N, Mishra S, Gardner SL, Raboud J, Fisman D, Cooper C, Gough K, Maxwell J, Rourke SB, Rousseau R, Mazzulli T, Salit IE, Allen VG. Burchell AN, et al. Among authors: rachlis a. Clin Infect Dis. 2022 Mar 9;74(5):846-853. doi: 10.1093/cid/ciab582. Clin Infect Dis. 2022. PMID: 34175944 Free PMC article. Clinical Trial.
277 results